Intranasal sufentanil for cancer-associated breakthrough pain

Good, P., Jackson, K., Brumley, D. and Ashby, M. (2009) Intranasal sufentanil for cancer-associated breakthrough pain. Palliative Medicine, 23 1: 54-58. doi:10.1177/0269216308100249


Author Good, P.
Jackson, K.
Brumley, D.
Ashby, M.
Title Intranasal sufentanil for cancer-associated breakthrough pain
Journal name Palliative Medicine   Check publisher's open access policy
ISSN 0269-2163
1477-030X
Publication date 2009-01
Sub-type Article (original research)
DOI 10.1177/0269216308100249
Open Access Status Not Open Access
Volume 23
Issue 1
Start page 54
End page 58
Total pages 5
Place of publication London, United Kingdom
Publisher Sage Publications
Language eng
Abstract The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO Medicalâ„¢ patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P < 0.0001) and 30 min (P < 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain.
Keyword Breakthrough pain
Cancer
Opioid
Sufentanil
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 16 Sep 2015, 16:34:47 EST by System User on behalf of School of Medicine